| Project/Area Number |
23K16036
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57040:Regenerative dentistry and dental engineering-related
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
周 君 東京医科歯科大学, 生体材料工学研究所, 特任助教 (40846507)
|
|---|
| Project Period (FY) |
2023-04-01 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2025: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2024: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | Wwp2 / mRNA theraputics / Osteoarthritis / mRNA therapy / osteoarthritis / temporomandibular joint |
|---|
| Outline of Research at the Start |
In this study, we propose a TMJOA therapy by using circular RNA (circRNA)-loaded polyplex nanomicelles. Wwp2 circRNA will be administered by intra-articular injection into the TMJ, and the therapeutic outcome will be evaluated by monitoring the nociceptive behaviors and level of inflammation. The molecular mechanisms of Wwp2 message RNA(mRNA) therapy will also be elucidated here.
|
| Outline of Annual Research Achievements |
Wwp2 mRNA was successfully established and treated in an in vitro chondrocyte-based osteoarthritis inflammation model using IL-1β induction. This model serves as a valuable tool for evaluating the therapeutic potential of Wwp2 mRNA in the context of OA-associated inflammation. Furthermore, we demonstrated that in vivo delivery of Wwp2 mRNA attenuates OA progression in an animal model, as evidenced by reduced cartilage damage.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
We totally have 4 aims in this project during the grant applicaiton. In the first year, we completed all tasks related to Aim 1, evaluating the biological function of Wwp2 mRNA therapy in vitro, including the construction of Wwp2 mRNA and the establishment of an in vitro chondrocyte-based OA inflammation model. We also partially fulfilled Aim 2 by developing linear Wwp2 mRNA.
|
| Strategy for Future Research Activity |
In the next stages, we will focus on the remaining objectives: completing Aim 2 (Wwp2 circRNA development), Aim 3 (delivery of Wwp2 circRNA using polyplex nanomicelles), and Aim 4 (investigating TMJOA treatment outcomes and mechanisms using Wwp2 circRNA delivery in vivo).
|
